Enactuzumab is produced and developed by which pharmaceutical company?

Elranatamab is an innovative targeted immunotherapy drug developed by Pfizer Inc., which mainly targets the treatment needs of patients with refractory or relapsed multiple myeloma (RRMM). Pfizer, as the world's leading biopharmaceutical company, has invested a lot of R&D resources in the field of tumor immunotherapy in recent years and is committed to developing a variety of innovative antibody drugs and bispecific T cell engagers. Among them, eractuzumab is one of its important products in the direction of hematological tumors.

Enactuzumabby simultaneously targeting the BCMA protein on the surface of tumor cells and the CD3 protein on the surface of T cells, activates T cells and guides them to recognize and kill myeloma cells. This mechanism has unique advantages in the treatment of multiple myeloma, especially for patients who have failed traditional treatments, have a high recurrence rate, or have received multiple lines of treatment.

In the process of developing eractuzumab , Pfizer has continuously optimized the dosing method in conjunction with clinical research. Currently, it is recommended to use subcutaneous injection to reduce the incidence of infusion reactions, and has designed a strategy of increasing dosage and interval treatment to improve patient tolerance and quality of life. According to the latest clinical progress, this drug has received accelerated approval from the US FDA for the treatment of specific RRMM populations, and has launched marketing application processes in multiple countries and regions.

In addition, Pfizer has established a complete drug safety monitoring and support plan for eractuzumab, covering pre-treatment risk assessment, dosing plan formulation, CRS and ICANS early identification and intervention mechanisms, etc., striving to ensure efficacy while reducing the incidence of toxic and side effects. Compared with CAR-T cell therapy, eractuzumab has the advantages of faster start-up, repeatable administration, and does not rely on the patient's autologous cells, so it is regarded as an important representative of "off-the-shelf" immunotherapy.

Reference materials:https://www.drugs.com/mtm/elranatamab.html